Accepted for Publication: September 14, 2011.
Author Contributions:Study concept and design: Wang and Rivera. Acquisition of data: Wang, Hessl, Hagerman, and Tassone. Analysis and interpretation of data: Wang, Hessl, Hagerman, and Rivera. Drafting of the manuscript: Wang and Hessl. Critical revision of the manuscript for important intellectual content: Wang, Hessl, Hagerman, Tassone, and Rivera. Statistical analysis: Wang. Obtained funding: Hessl, Hagerman, and Rivera. Administrative, technical, and material support: Hagerman and Rivera. Study supervision: Hessl and Rivera.
Financial Disclosure: Dr Wang receives support as a postdoctoral fellow from the National Institutes of Health. Dr Hessl receives grant support from Roche, Novartis, and Seaside Therapeutics for treatment trials in fragile X syndrome and research support from the National Institutes of Health. Dr Hagerman receives grant support from Roche, Novartis, Seaside Therapeutics, Forest, Johnson and Johnson, and Curemark for treatment trials in fragile X or autism and research support from the National Institutes of Health and the National Fragile X Foundation. Dr Tassone receives research support from the National Fragile X Foundation, UC Davis Health System Research Award, and the National Institutes of Health. Dr Rivera receives research support from the National Institutes of Health.
Funding/Support: This work was supported by National Institutes of Health grants HD036071, MH078041, MH077554, NS062412, UL1DE019583, RL1AG032119, RL1AG032115, and TL1DA024854.
Additional Contributions: We are grateful to the research participants and their families; to Jenny Tram, BS, Jose Fon, BS, and John Shell, BS, for performing fiber tracking; Jim Grigsby, PhD, John Wang, BS, and Patrick Adams, BS, for image and data collection; and Danielle Harvey, PhD, for statistical support.
This article was corrected for errors on May 4, 2012.